Literature DB >> 26461115

Enabling dual cellular destinations of polymeric nanoparticles for treatment following partial injury to the central nervous system.

I Lozić1, R V Hartz2, C A Bartlett2, J A Shaw3, M Archer2, P S R Naidu1, N M Smith1, S A Dunlop2, K Swaminathan Iyer4, M R Kilburn3, M Fitzgerald5.   

Abstract

Following neurotrauma, oxidative stress is spread via the astrocytic syncytium and is associated with increased aquaporin 4 (AQP4), inflammatory cell infiltration, loss of neurons and glia and functional deficits. Herein we evaluate multimodal polymeric nanoparticles functionalized with an antibody to an extracellular epitope of AQP4, for targeted delivery of an anti-oxidant as a therapeutic strategy following partial optic nerve transection. Using fluorescence microscopy, spectrophotometry, correlative nanoscale secondary ion mass spectrometry (NanoSIMS) and transmission electron microscopy, in vitro and in vivo, we demonstrate that functionalized nanoparticles are coated with serum proteins such as albumin and enter both macrophages and astrocytes when administered to the site of a partial optic nerve transection in rat. Antibody functionalized nanoparticles synthesized to deliver the antioxidant resveratrol are effective in reducing oxidative damage to DNA, AQP4 immunoreactivity and preserving visual function. Non-functionalized nanoparticles evade macrophages more effectively and are found more diffusely, including in astrocytes, however they do not preserve the optic nerve from oxidative damage or functional loss following injury. Our study highlights the need to comprehensively investigate nanoparticle location, interactions and effects, both in vitro and in vivo, in order to fully understand functional outcomes.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Central nervous system injury; Macrophages; Nanoscale secondary ion mass spectroscopy (NanoSIMS); Oxidative stress and aquaporin 4; Polymer nanoparticles; Targeted drug delivery of antioxidants

Mesh:

Substances:

Year:  2015        PMID: 26461115     DOI: 10.1016/j.biomaterials.2015.10.001

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  6 in total

1.  Oligodendroglia Are Particularly Vulnerable to Oxidative Damage after Neurotrauma In Vivo.

Authors:  Marcus K Giacci; Carole A Bartlett; Nicole M Smith; K Swaminathan Iyer; Lillian M Toomey; Haibo Jiang; Paul Guagliardo; Matt R Kilburn; Melinda Fitzgerald
Journal:  J Neurosci       Date:  2018-06-18       Impact factor: 6.167

2.  Characterization of polymeric nanoparticles for treatment of partial injury to the central nervous system.

Authors:  Ivan Lozić; Richard V Hartz; Carole A Bartlett; Jeremy A Shaw; Michael Archer; Priya S R Naidu; Nicole M Smith; Sarah A Dunlop; K Swaminathan Iyer; Matt R Kilburn; Melinda Fitzgerald
Journal:  Data Brief       Date:  2016-02-16

Review 3.  Biopolymer Nanoparticles for Nose-to-Brain Drug Delivery: A New Promising Approach for the Treatment of Neurological Diseases.

Authors:  Nicolò Montegiove; Eleonora Calzoni; Carla Emiliani; Alessio Cesaretti
Journal:  J Funct Biomater       Date:  2022-08-24

Review 4.  Aquaporin Membrane Channels in Oxidative Stress, Cell Signaling, and Aging: Recent Advances and Research Trends.

Authors:  Grazia Tamma; Giovanna Valenti; Elena Grossini; Sandra Donnini; Angela Marino; Raul A Marinelli; Giuseppe Calamita
Journal:  Oxid Med Cell Longev       Date:  2018-03-27       Impact factor: 6.543

Review 5.  Aquaporins as Targets of Dietary Bioactive Phytocompounds.

Authors:  Angela Tesse; Elena Grossini; Grazia Tamma; Catherine Brenner; Piero Portincasa; Raul A Marinelli; Giuseppe Calamita
Journal:  Front Mol Biosci       Date:  2018-04-18

6.  Novel Hydrophilic Copolymer-Based Nanoparticle Enhances the Therapeutic Efficiency of Doxorubicin in Cultured MCF-7 Cells.

Authors:  Priya S R Naidu; Marck Norret; Sarah A Dunlop; Melinda Fitzgerald; Tristan D Clemons; K Swaminathan Iyer
Journal:  ACS Omega       Date:  2019-10-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.